$2.45
Relmada Therapeutics is a biotechnology business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Relmada Therapeutics stock
How to buy Relmada Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RLMD. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Relmada Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Relmada Therapeutics stock price (NASDAQ: RLMD)
Use our graph to track the performance of RLMD stocks over time.Relmada Therapeutics shares at a glance
Latest market close | $2.74 |
---|---|
52-week range | $1.88 - $7.22 |
50-day moving average | $3.26 |
200-day moving average | $3.79 |
Wall St. target price | $10.13 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.87 |
Is it a good time to buy Relmada Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Relmada Therapeutics price performance over time
Historical closes compared with the close of $2.74 from 2024-09-03
1 week (2024-08-29) | 3.79% |
---|---|
1 month (2024-08-05) | -19.17% |
3 months (2024-06-05) | -7.43% |
6 months (2024-03-05) | -56.65% |
1 year (2023-09-05) | -27.51% |
---|---|
2 years (2022-09-02) | -90.78% |
3 years (2021-09-03) | 24.4 |
5 years (2019-09-05) | 10.28 |
Relmada Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -59.13% |
Return on equity TTM | -100.41% |
Profit margin | 0% |
Book value | $2.04 |
Market Capitalization | $84.5 million |
TTM: trailing 12 months
Relmada Therapeutics share dividends
We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.
Have Relmada Therapeutics's shares ever split?
Relmada Therapeutics's shares were split on a 1:4 basis on 29 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.
Relmada Therapeutics share price volatility
Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $1.88 up to $7.2225. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.507. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).
Relmada Therapeutics overview
Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. .
Frequently asked questions
What percentage of Relmada Therapeutics is owned by insiders or institutions?Currently 8.037% of Relmada Therapeutics shares are held by insiders and 46.165% by institutions. How many people work for Relmada Therapeutics?
Latest data suggests 20 work at Relmada Therapeutics. When does the fiscal year end for Relmada Therapeutics?
Relmada Therapeutics's fiscal year ends in December. Where is Relmada Therapeutics based?
Relmada Therapeutics's address is: 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134 What is Relmada Therapeutics's ISIN number?
Relmada Therapeutics's international securities identification number is: US75955J4022 What is Relmada Therapeutics's CUSIP number?
Relmada Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75955J402
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question